

Amendments to the Claims

1-8. (Cancelled)

9. (Currently amended) A vaccine composition for inducing an immune response in a ruminant, said vaccine composition comprising recombinant MSP1a in combination with an immunogen derived from *A. marginale*, wherein said immunogen is not isolated or recombinant MSP1b and said vaccine composition further comprises a pharmaceutically acceptable carrier or diluent.

10. (Previously presented) The vaccine according to claim 9, wherein said immunogen is tick cell culture derived *A. marginale*.

11. (Previously presented) The vaccine according to claim 10, wherein said tick cell culture comprises *Ixodes scapularis* tick cell line IDE8.

12. (Previously presented) The vaccine according to claim 9, wherein said recombinant MSP1a is from the Oklahoma isolate of *A. marginale*.

13. (Previously presented) The vaccine according to claim 12, wherein said immunogen is derived from the Oklahoma isolate of *A. marginale*.

14. (Previously presented) A method for inducing a protective immune response in a ruminant against *A. marginale* comprising administering to the ruminant an effective dose of the vaccine composition of claim 9.
15. (Previously presented) The method according to claim 14, wherein said dose comprises approximately 100 µg of said recombinant MSP1a.
16. (Cancelled)
17. (Previously presented) The method according to claim 14, wherein said immunogen of said vaccine composition is tick cell culture derived *A. marginale*.
18. (Previously presented) The method according to claim 17, wherein said tick cell culture comprises *Ixodes scapularis* tick cell line IDE8.
19. (Previously presented) The method according to claim 14, wherein said recombinant MSP1a of said vaccine composition is from the Oklahoma isolate of *A. marginale*.

PATENT

Attorney Docket No.: 67686/00-602
Amendment and Response to Office Action
Page 4

20. (Previously presented) The method according to claim 19, wherein said immunogen of said vaccine composition is derived from the Oklahoma isolate of *A. marginale*.
21. (Previously presented) The method according to claim 17, wherein said dose comprises approximately 2×10^{10} of said tick cell culture derived *A. marginale*.
22. (Previously presented) The vaccine composition according to claim 9, wherein said recombinant MSP1a is associated to *E. coli* membrane fractions.